Acorda Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Acorda Therapeutics (ACOR) Tops Q2 EPS by 13c
August 4, 2020 4:39 PM EDTAcorda Therapeutics (NASDAQ: ACOR) reported Q2 EPS of ($0.35), $0.13 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $33.62 million versus the consensus estimate of $27.4 million.
We were pleased with INBRIJAs performance in the second quarter, especially in light of the significant disruption of COVID-19. Net sales increased by 7% over the first quarter, and dispensed cartons, which reflect actual demand,... More
